Brief: Genprex Signs Exclusive License To Additional Diabetes Technology With University Of Pittsburgh
18/07/2023 14:13
July 18 (Reuters) - Genprex Inc GNPX.O :
* GENPREX SIGNS EXCLUSIVE LICENSE TO ADDITIONAL DIABETES
TECHNOLOGY WITH THE UNIVERSITY OF PITTSBURGH
Source text for Eikon: ID:nPn5LSZ4Ra
Further company coverage: GNPX.O
Recent news on Genprex
See all newsBrief: Genprex Announces Collaboration With Roche Diagnostics For Biomarker Assay Validation Studies
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy